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PITUITARY ADENYLATE CYCLASE-ACTIVATING POLYPEPTIDE 
REGULATES EXCESSIVE ALCOHOL CONSUMPTION 
 
ANDREW KIM 
 
ABSTRACT 
 Alcoholism results from an interaction between genetic and environmental 
factors. However, the neurobiological mechanisms mediating the propensity to 
consume excessive amounts of alcohol are still not well understood. Using 
genetically selected alcohol-preferring rats, a well-established animal model of 
alcoholism, we demonstrate that central administration of a peptide antagonist for 
the pituitary adenylate cyclase-activating polypeptide receptor 1 (PAC1), the 
cognate receptor for the neuropeptide pituitary adenylate cyclase-activating 
polypeptide (PACAP), blocks excessive alcohol drinking as well as motivation to 
drink. On the other hand, the PAC1 antagonist does not significantly affect water 
intake, saccharin intake, or responding for ethanol in non-selected outbred Wistar 
rats. In addition, the antagonist significantly reduced responding maintained by 
alcohol-associated incentive stimuli (alcohol seeking behavior). Using 
immunohistochemistry, a significant reduction in the number of PAC1 positive 
cells was observed selectively in the Nucleus Accumbens (NAcc) Core of 
alcohol-preferring compared to Wistar rats. Proving the functional relevance of 
these changes, excessive drinking in alcohol-preferring rats was markedly 
  v 
reduced following microinfusion of the PAC1 antagonist into the Core, but not the 
Shell, of the NAcc. Finally, using retrograde tracing techniques coupled with 
immunofluorescence, we show that the dopaminergic neurons of the VTA which 
project to the NAcc core co-express PACAP. Altogether, our findings 
demonstrate that the dysregulation of the PACAP/PAC1R system, specifically in 
the NAcc core, promotes excessive drinking and alcohol-seeking behavior, 
indicating that blockade of the PACAP/PAC1R system may represent a novel 
target for alcohol addiction. 
  
  vi 
TABLE OF CONTENTS 
 
TITLE……………………………………………………………………………………...i 
COPYRIGHT PAGE……..……………………………………………………………...ii 
READER APPROVAL PAGE…...……………………………………………………..iii 
ABSTRACT ..........................................................................................................iv 
TABLE OF CONTENTS .......................................................................................vi 
LIST OF FIGURES .............................................................................................. vii 
LIST OF ABBREVIATIONS ................................................................................ viii 
INTRODUCTION .................................................................................................. 1 
METHODS............................................................................................................ 9 
RESULTS ........................................................................................................... 18 
DISCUSSION ..................................................................................................... 30 
LIST OF JOURNAL ABBREVIATIONS .............................................................. 38 
REFERENCES ................................................................................................... 40 
CURRICULUM VITAE ........................................................................................ 47 
 
  
  vii 
LIST OF FIGURES 
 
 
 
 Title Page 
 Fig. 1 19 
 Fig. 2 21 
 Fig. 3 23 
 Fig. 4 25 
 Fig. 5 27 
 Fig. 6 28 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  viii 
LIST OF ABBREVIATIONS 
 
BNST……………………………………………..Bed nucleus of the stria terminalis 
CRF…………………………………………………….Corticotropin-releasing factor 
NAcc………………………………………………………………Nucleus accumbens 
PVN…………………………………………………………...Paraventricular nucleus 
PACAP…………………………….Pituitary Adenylate Cyclase Activating Peptide 
VTA…………………………………………………………....Ventral Tegmental Area 
 
 1 
 
INTRODUCTION 
 
Alcohol Addiction 
 Alcohol addiction is a debilitating disorder that affects over 140 million 
people worldwide (1). In 2002, the World Health Organization estimated that 
alcohol causes 1.8 million deaths and 58.3 million of disability-adjusted life years; 
the organization has also stated that patterns of heavy drinking exist in most 
developed countries (1). To put this in perspective, alcohol has a greater toll on 
world health than tobacco and is on par with unsafe sex, measles, and malaria. 
According to the Center of Disease Control, between 2006 and 2010 over 87,000 
deaths per year, which translates into 1 in 10 deaths in the same time span in the 
United States, were attributed to alcohol-related issues (67). The economic pitfall 
of alcohol abuse in 2006 was estimated to be $223.5 billion (67).  
Alcoholism is characterized by uncontrolled heavy drinking as well as 
craving and seeking. Its etiology is complex, as heritable susceptibility factors 
contribute to 50-60% of the disease risk and interact with environmental factors 
that produce and maintain the disorder, pointing to specific genotypes that are 
particularly susceptible to addiction and addictive behavior (4). Genetic factors 
and neuroadaptations resulting from continuous alcohol consumption can, in fact, 
act independently to generate the same phenotypes, indicating that the alcohol 
addiction phenotype can be acquired through slow changes in neural pathways 
with consistent exposure to alcohol; the molecular correlates of the genetic 
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propensity to drink can be duplicated environmentally by chronic ethanol 
exposure.  
   
Pituitary Adenylate Cyclase Activating Polypeptide (PACAP) 
In this context, we investigated the neuropeptide pituitary adenylate 
cyclase-activating polypeptide (PACAP). Originally isolated from the ovine 
hypothalamus (10), PACAP is encoded by the Adcyap1 gene. PACAP belongs to 
a superfamily which includes growth hormone-releasing hormone, secretin, and 
vasoactive intestinal peptides, and it exists in two different fragments, PACAP-38 
and PACAP-27 (10, 11). The most abundant population of PACAP-containing 
neurons, as well as the highest density of PACAP binding sites, is found in the 
hypothalamus; PACAP-containing neurons are also found in the bed nucleus of 
the stria terminalis and the amygdala (62). The neurons are found mainly in the 
paraventrinuclear and supraoptic nuclei. Importantly, Three PACAP receptors 
have been characterized; two of them, VPAC1 and VPAC2, recognize both VIP 
and PACAP with equal affinity, while the third, PAC1, is a PACAP-selective 
receptor (12). Interestingly, the PACAP antagonist PACAP(6-38) blocks PAC1 
receptors and does not interact with VPAC1, but does have an affinity for 
VPAC2. The large amount of immunoreactivity in the hypothalamus for PACAP 
suggests that PACAP plays a role in many hypothalamically regulated 
processes. Indeed, the PACAP/PAC1 system has been demonstrated to regulate 
food intake, energy metabolism, body temperature, and neuronal survival (13-
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15). Central administration of PACAP has been shown to reduce feeding in both 
normal and food-restricted conditions. Furthermore, injections cause rapid 
elevations in core body temperature and spontaneous locomotor activity (15). 
Several groups including ours have shown that the PACAP system is a strong 
mediator of the behavioral response to stress. PACAP has been shown to 
increase substantially in the anterolateral BNST of rats exposed to chronic 
variable stress compared to non-stressed rats. 
 PACAP fibers were also shown to innervate hypothalamic CRF neurons 
in the praventricular nucleus (PVN) and extrahypothalamic CRF neurons in the 
BNST (16, 17). PACAP has been linked to the production of CRF as 
administration of PACAP causes increase in CRF gene expressions (17, 63). 
The anxiogenic and anti-rewarding effects of PACAP have been shown to be 
mediated by the recruitment of the central CRF system, especially in the central 
amygdala (17). However, PACAP also acts independently of the CRF system. 
PACAP induces an anorectic effect, causing a dramatic reduction in food intake 
and body weight; this effect is not blocked by CRF receptor antagonist, 
suggesting that some effects of PACAP do not involve the CRF system (17). 
Based on these findings, it is clear that PACAP plays a significant role in the 
stress response system both dependent and independently of CRF. 
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Alcohol Addiction and the PACAP/PAC1 System 
 A growing body of evidence links the PACAP/PAC1 system with the 
actions of drugs of abuse and alcohol. Morphine-induced motor stimulation and 
conditioned place preference are potentiated by low doses of PACAP, and they 
are blunted in PACAP-deficient mice compared to their wild-type counterparts, 
suggesting that endogenous PACAP positively modulates the acute actions of 
morphine (20). It is also found that PACAP-deficient mice display an increase in 
basal motor activity, and PAC1 receptor deletion results in a similar increase in 
basal motor activity; the effect of exogenous PACAP on motor stimulation 
suggests that this abnormal behavior displayed in PACAP-deficient mice is due 
to the lack of peptide in the brain’s reward and stress system (20). It is likely that 
PAC1 receptors play a role in PACAP’s inhibition on motor activity (20). Studies 
on the intoxicating and ataxic effects of ethanol in Drosophilia led to the 
identification of a mutation (named “Cheapdate”) with higher sensitivity to 
ethanol-induced ataxia, due to an allele of the gene that encodes PACAP (21).  
PACAP signaling likely mediates the response that produces the acute 
tolerance to ethanol-induced ataxia, diminishing the intoxication actions of 
ethanol. Thus, high amounts of PACAP may lead to a higher preference for 
alcohol, as less-impaired motor control during the early stages of drinking seems 
linked to a greater risk of long-term alcohol addiction (22, 23). Those that 
experience a lower level of intoxication at lower blood alcohol levels may have a 
greater likelihood of consuming larger amounts in order to obtain effects similar 
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to those experienced by others with lower amounts of alcohol consumed, which 
would then lead to the development of both behavioral and pharmacological 
tolerance (22). In addition, acute ethanol increases PAC1 receptor mRNA levels 
via RACK1 (24), which most likely results in an enhancement in PACAP 
signaling. The PAC1 gene contains an AP-1 site upstream of its promoter region 
(24), a transcription factor known to regulate gene expression in response to 
stress, which may explain the effect of ethanol on the PAC1 mRNA levels. 
PACAP is also able to counteract the toxic effects of ethanol in cerebellum in vivo 
while also attenuating the expression of pro-apoptotic genes that are increased 
by alcohol (25). PACAP did not modify plasma alcohol levels and administering 
the peptide early in the life of the rats was enough to counteract the toxic effects 
of alcohol and improved cerebellar function (25). Importantly, not only does 
PACAP reduce the amount of neuronal cell death caused by alcohol, but it also 
promotes cell differentiation, a key element in functional recovery from damage 
caused by ethanol intoxication (25). Interestingly, PACAP modulates the 
hypothermic and hypnotic effects of ethanol; PACAP-/- mice were less sensitive in 
both effects than wild-type mice to intoxicating blood ethanol levels (26). PAC1 
receptors show normal sensitivity to ethanol, and since PAC1 receptor-deficient 
mice showed normal sensitivity to ethanol, the VPAC receptors are likely 
responsible for the reduced sensitivity to ethanol in the PACAP-/- mice.  
Furthermore, mice deficient in a subunit of protein kinase A showed low 
sensitivity to intoxicating levels of ethanol in the blood, suggesting that the cyclic 
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AMP-protein kinase A system, the main pathway of the VPAC receptors, is 
involved in ethanol response (68). 
 Remarkably, a single nucleotide polymorphism of ADCYAP1 (Asp54Gly) 
with potential relevance to alcohol drinking (g/kg/week) was identified in a Finnish 
population of social drinkers (the recessive model of the GG genotype 
predisposes individuals to higher levels of intake); individuals of this genotype 
showed a significant increase in risk of alcohol dependence as compared to the 
wild-type (27). Those with the recessive genotype required a larger number of 
drinks needed to obtain an effect of the alcohol during their first five times 
drinking ever, suggesting those with the genotype have low sensitivity to alcohol 
(27).  
PACAP cell bodies and fibers are found in high quantities in hypothalamic 
nuclei, as well as in various extra-hypothalamic regions. PACAP-38 mRNA was 
also found in high amounts in the hypothalamus, suggesting that PACAP is 
processed and released close to where it is synthesized; strikingly, PACAP is not 
found in the rat anterior pituitary gland, suggesting it is not locally synthesized 
within the pituitary but rather is released through neurons from different sites and 
thus resembles other hypophysiotrophic hormones in effect (28). The nucleus 
accumbens (NAcc) and the ventral tegmental area (VTA) are among the brain 
regions expressing the highest levels of PACAP, specifically PACAP-38, 
immunoreactivity (28), suggesting that the PACAP/PAC1 system might interact 
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with the function of the mesolimbic dopaminergic system implicated in the 
rewarding effects of alcohol. 
The relationship between the PACAP/PAC1 system and alcohol 
reinforcement and addiction remains unclear. We used a line of alcohol-
preferring Sardinian rats, genetically selected for alcohol preference and 
consumption, to unravel the neurobiological factors underlying the predisposition 
to consume excessive quantities of alcohol, an effective approach often used in 
preclinical research (8, 9). These rats exhibit the fundamental signs of 
alcoholism: they ingest alcohol orally, voluntarily consume doses of alcohol that 
result in pharmacologically significant blood alcohol levels, which suggests that 
they do not consume alcohol due to taste, smell, or caloric properties, are willing 
to work for alcohol, e.g. lever-pressing, to obtain alcohol, and voluntarily 
consume alcohol to an extent such that tolerance is able to develop (65). 
However, it is not clear whether or not they develop signs of physical 
dependence after voluntary alcohol consumption and the alcohol is removed. A 
likely explanation for this behavior, which is considerably different from the wild-
type, is the difference in genotypes that causes these rats to have high alcohol 
preference and consumption.  
The present studies aimed to determine if the PACAP/PAC1 system 
played a role in alcohol reinforcement by exploring whether or not the PACAP 
antagonist PACAP(6-38) would reduce excessive alcohol intake during operant 
conditioning in alcohol-preferring rats, as well as determining the selectivity of the 
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effect of PACAP by testing the antagonist PACAP(6-38) with saccharin intake in 
alcohol-preferring rats. The present studies also aimed to explore the role of the 
PACAP/PAC1 system in motivation for alcohol in alcohol-preferring rats by 
determining the efficacy of the antagonist PACAP(6-38) in a progressive ratio 
test of operant conditioning. Finally, the present studies aimed to study the 
neurobiology of the PACAP fibers and PAC1 receptors in the brain, especially in 
the VTA and NAcc, as well as to explore any differences between in the inherent 
neurobiology of alcohol-preferring rats and outbred Wistar rats. 
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METHODS 
 
Subjects 
  Subjects of this study were male Wistar rats, 225-250 grams upon arrival 
(Charles River, Wilmington, MA, USA) and male rats derived from the TSRI 
Sardinian alcohol-preferring (sP) rats (Scr:sP 29-30th generation, 
http://rgd.mcw.edu/rgdweb/report/strain/main.html?id=2302666) maintained for 
12 generations at Boston University without further selective breeding. Scr:sP 
rats were generated from intra-line breeding at The Scripps Research Institutde 
from sP rats generously provided after 32 generations of selective breeding from 
Prof. G. L. Gessa (University of Cagliari, Italy). Rats were chosen for breeding 
only if their alcohol intake was 4 g/kg or higher and they showed a preference 
ratio of twice the amount of alcohol intake as compared to water intake. Subjects 
were housed in an AAALAC-approved vivarium on a 12-h light-dark cycle (lights 
off at 9:00 a.m.), with water and regular rodent chow available ad libitum. 
Experiments were conducted during the rats’ dark cycle. Procedures adhered to 
the National Institutes of Health Guide for the Care of Use of Laboratory Animals 
and the Principles of Laboratory Animal Care and were approved by Boston 
University Medical Campus Institutional Animal Care and Use Committee. 
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Drugs 
 Ethanol solution (10% w/v) was prepared using 95% ethyl-alcohol and tap 
water. Saccharin solution (0.02% w/v) was prepared using saccharin sodium 
hydrate (Sigma Aldrich, St. Louis, MI) and tap water. PACAP 6-38 was 
purchased from the American Peptide Company (Sunnyvale, CA). The peptide 
was dissolved in sterile isotonic saline in the presence of 1% bovine serum 
albumin (Sigma Aldrich, St. Louis, MI) and was administered 30 minutes before 
the experimental sessions. Testing began when performance stabilized (<20% 
variation across three consecutive sessions). Experiments followed a within-
subject design and at least two treatment-free days were allowed between 
treatment days.  
 
Intracranial surgery and mincroinfusion procedure 
 Surgeries: The surgical procedures were performed as previously 
described (1, 2). Rats underwent unilateral (for intracerebroventricular (i.c.v.) 
experiments) or bilateral (for Nucleus Accumbens (NAcc) core and shell) 
implantation for 24-gauge stainless steel cannulas (Plastics One, Roanoke, VA) 
under stereotaxic control (Kopf Instruments, Tujunga, CA), using the following 
coordinates (from bregma, in mm, DV from skull): i.c.v.: AP -1.0 ML: ± 1.5, DV: -
2.3. NAcc core: AP: +1.4, ML: ± 2.4, DV: -5.6; NAcc shell: AP: +1.06, ML: ±0.75, 
DV: -5.7. NAcc core surgery was performed with a <6 degree angle to avoid the 
 11 
 
ventricles. The incisor bar was set at -3.3 mm from the interneural line for all 
surgeries. 
 Microinfusion procedure: For i.c.v. and site-specific microinfusions, the 
dummy stylet was removed from the guide cannula and was replaced with a 31-
gauge stainless steel injector projecting 2.5mm and 1.5mm, respectively, beyond 
the tip of the guide cannula, which was connected via a polyethylene 20 tubing to 
a Hamilton microsyringe driven by a microinfusion pump (KD Scientifics, 
Holliston, MA). Two days prior to test days, subjects were shammed to simulate 
injections using 31-gauge stainless steel injectors projecting 2.5mm and 1.5mm, 
respectively, beyond the tip of the guide cannula, which was connected to an 
empty polyethylene tubing. Microinjections were performed in a 5 µl (for i.c.v.) 
and 0.5 µl/side (for NAcc) volume, delivered over one minute; injectors were left 
in place for an additional minute to minimize backflow. I.c.v. cannula placement 
was functionally verified at the end of experiments as a positive dipsogenic 
response (>5ml water intake within 15 min) to an i.c.v. injection of angiotensionII 
(25 ng/5 µl). For verification of site-specific cannula placement, subjects were 
microinfused with India ink (0.5 µl/side); coronal sections of a 40 µl were 
collected using a cryostat and placements were verified under a microscope. 
 
Apparatus for operant oral ethanol/saccharin self-administration 
 The test chambers used for operant oral self-administration (Med 
Associates, Inc., St. Albans, VT) were located in sound-attenuating, ventilated 
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cubicles. Two separate syringe pumps (Med Associates, St. Albans, VT) were 
used: one that dispensed ethanol or saccharin into the right-side stainless steel 
drinking cup mounted 2 centimeters above the grid floor, and one that dispensed 
water into the left-side drinking cup. Both cups were located in the middle of one 
side panel. Two retractable levers were located 3.2 cm to either side of the 
drinking cups. One lever responded with the syringe of ethanol or saccharin and 
the other responded with the syringe of water. Fluid delivery and operant 
responses were controlled by microcomputers.  
 
Self-administration procedure: Fixed Ratio-1 schedule of reinforcement 
 Rats were first allowed continuous (24 hr/day) two-bottle choice access to 
ethanol (10% w/v) and water in their home cages for 1 week, and then allowed 
limited daily access (2 hr/day) for 3-4 days. Rats were then allowed 1-3 overnight 
two-choice operant access to ethanol and water with chow available ad libitum; 
sessions lasted for 16 hours and the number of sessions for each subject 
depended on the amount of lever presses each subject performed in each 
overnight trial. 
 For saccharin, rats were trained to self-administer a saccharin solution 
(0.02% w/v). Rats were then allowed 1-3 overnight two-choice operant access to 
saccharin and water with chow available ad libitum; sessions lasted for 16 hours 
and the number of sessions for each subject depended on the amount of lever 
presses each subject performed in each overnight trial. Each response of the 
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right-side lever resulted in the delivery of 0.1 ml of fluid (ethanol or saccharin) 
and sessions were 30 minutes in duration. Lever presses had no scheduled 
consequences if pressed repeatedly within 2.01 seconds after activation of the 
pumps to avoid double responses. During all sessions, rats were also allowed to 
press for water on the opposite lever. Each response of the left-side lever 
resulted in delivery of 0.1 ml of water. 
 
Self-administration procedure: Progressive Ratio schedule of 
reinforcement 
 Scr:sP and Wistar rats were trained to self-administer 10% w/v ethanol 
under a Progressive Ratio (PR) schedule of reinforcement. Under this schedule, 
the number of responses required to produce one delivery of 0.1 ml of ethanol 
(10% w/v) increased with successive deliveries based on the following 
exponential progression: response ratio = 4 × (e# of reinforcer*0.1) − 3.8, 
rounded to the nearest integer as in (3). Start of the session was defined upon 
completion of the first ratio, with the latency to complete the first ratio recorded as 
a dependent measure, and set to a maximum of 2 hours. To avoid unintended 
session starts, the first reinforcement required three responses. Thus, the PR 
schedule was 3, 1, 2, 2, 3, 3, 4, 5, 6, 7, 8, 9, 11, 12, 14, 16, 18, 20, 23, etc. 
responses; sessions ended when subjects had not completed a ratio for 14 
minutes, as we and others previously reported (3-5), with the last completed ratio 
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defined as the breakpoint, the point at which the subjects ceases to work for 
ethanol reward. Responses on the inactive lever were also recorded. 
 
Alcohol-seeking behavior: Second-order schedule of reinforcement 
 Active and inactive levers were counterbalanced throughout the study 
between left and right sides. Subjects were trained to press a lever to acquire 
0.05 ml of 10% w/v ethanol solution under a fixed ratio 1 (FR1) schedule of 
reinforcement. Responses on the inactive lever had no programmed 
consequences, but were recorded as an index of motor activity. Lever presses on 
the active lever resulted in ethanol solution delivery concomitantly with 
illumination of a conditioned stimulus (CS) light above the active lever for 20 
seconds (time out, TO) followed by lever retraction. The session ended when 
subjects reached 30 rewards or after 2 hours, whichever occurred first. Subjects 
were then introduced to the next step of the training, a fixed interval (FI) schedule 
of reinforcement. The FI schedule increased daily from FI1 minute, to FI2, FI4, 
FI8, and FI10 minutes before stabilizing at FI15 minutes. After the FI schedule, a 
press on the active lever resulted in solution delivery. The volume of solution 
delivered after the FI progressively increased from 0.05 to 0.12 ml according to 
the FI schedule. The session ended when subjects received 30 rewards or after 
2 hours. Finally, subjects were moved to a second-order schedule of 
reinforcement. The second order schedule was comprised of two 15-minute fixed 
intervals. During the FI15min, every 10th active lever press resulted in a brief CS 
 15 
 
presentation for 1 second above the active lever (FI15(FR10:S)); after the FI15 
min, ten active lever presses resulted in a delivery of 0.12 ml of ethanol solution 
and CS presentation for 20 seconds. The session ended when subjects 
completed two intervals or after 40 minutes, whichever occurred first. 
 
Immunohistochemistry 
 Fixation: rats were anesthetized with isoflurane and transcardially 
perfused with phosphate buffered saline (PBS) first and then in 4% 
paraformaldehyde (PFA). Brains were collected, placed in PFA, and stored in a 
30% sucrose PBS solution at 4°C until saturation. Brains were then cut into 30 
μm coronal sections using a cryostat and subsequently stored in a cryoprotectant 
at -20°C until processed for immunohistochemistry. 
 PAC1 immunohistochemistry: every 12th section (240 μm apart; bregma 
+2.28 to +0.84 mm) of the NAcc Core, Shell, and Dorsal Striatum (DS) regions 
were collected in a systematic manner and processed for immunohistochemistry. 
Sections were subject to an antigen retrieval step (6M Urea solution, pH=9.5 in 
0.1M Tris HCl at 95°C for 10 min). After rinsing, incubation in 1% hydrogen 
peroxide TBS solution to quench endogenous peroxidases, additional rinsing and 
a blocking step (5% normal goat serum, 3% Triton X100, and 5% bovine serum 
albumin), sections were incubated in an anti-PAC1R primary antibody in blocking 
solution for 48 h at 4°C (1:250, Santa Cruz, Biotechnology, Dallas, TX). Sections 
were then rinsed and incubated in an anti-PAC1R primary antibody in in a 
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biotinylated anti-rabbit secondary antibody (1:200, Vector Labs, Burlingame, CA) 
and immunoreactivity was visualized using a diaminobenzidine substrate kit 
(Vector Labs, Burlingame, CA) according to the manufacturer’s instructions. 
Slides were dehydrated using graded alcohol concentrations and then cover 
slipped.  
 Fluorescence immunohistochemistry: We used a retrograde tracing 
technique coupled with immunofluorescence to determine whether the 
dopaminergic neurons of the VTA which projected to the NAcc core also 
contained PACAP. Rats were stereotaxically injected with 0.1 µl of a 4% w/v 
FluoroGold solution (retrograde axonal tracer) into the NAcc core (6, 7). 7 days 
later rats were anesthetized, perfused as described above, and brains removed 
for immunofluorescent quantification of FluoroGold/TH/PACAP triple-labeled 
neurons. FluoroGold-labeled sections which included the VTA (bregma +2.28 to 
+0.84 mm) were washed in TBS between each blocking and incubation step. 
Sections were first placed in a blocking solution(3% normal goat serum and 
0.25% bovine serum albumin). Subsequently, sections were incubated for 24 hr 
with rabbit anti-PACAP (1:500, Bachem, Torrance, CA) and mouse anti-TH 
(1:500 EMD Millipore, Billerica, MA) in blocking solution. Then for 2 hr with 
biotinylated goat anti-rabbit (Vector Labs, Burlingame, CA) with Alexa Fluor 488 
goat anti-mouse (Jackson ImmunoResearch, West Grove, PA) in blocking 
solution; finally sections were placed in streptavidin Cy3 (Jackson 
ImmunoResearch, West Grove, PA) in blocking solution. 
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Microscopy 
 Sections from the PAC1 and the fluorescent immunohistochemical 
experiments were analyzed using an Olympus (Center Valley, PA) BX-51 
microscope equipped with a Rotiga 2000R live video camera (Ludl Eelctronics, 
Hawthorne, NY), and a EXFO X-cite Series 120 fluorescent illuminator (EXFO, 
Vanier, Quebec, Canada). 
 Quantification of PAC1 positive cells were performed in accordance with 
an unbiased stereology approach. Serial sections were created virtually using the 
number of sections per slide, the thickness in micrometers of each section, and 
the actual thickness of each section after preparation and dehydration in order to 
create a virtual 3-D representation of the regions outlined. Each region was 
outlined virtually and individually on the digitized image of each section using the 
optical fractionator workflow module of Stereo Investigator software 
(MicroBrightField, Williston, VT). One hemisphere was randomly chosen for each 
section; contours were drawn at low magnification using an Olympus PlanApo N 
2X objective with numerical aperture 0.08 and counted using Olympus UPlanFL 
N 40X objective with numerical aperture 0.75. Each group of brains was counted 
by the same person to avoid differences in perception of cell bodies as well as to 
minimize discrepancies between cell counts in the brains.   
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 RESULTS  
 
I.c.v. PACAP (6-38) blocked excessive ethanol self-administration in 
alcohol-preferring, but not in outbred rats 
 As shown in Fig. 1, Scr:sP rats responded excessively for ethanol 
compared to control outbred Wistar rats under an FR1 schedule of reinforcement 
(panel A vs. panel C; Genotype: F(1, 13)=4.95, p<0.05). I.c.v. administration of 
the PAC1R antagonist PACAP (6-38) selectively and dose-dependently blocked 
excessive ethanol self-administration in Scr:sP rats (Fig. 1A), but not in outbred 
Wistar rats (Fig. 1C), as reflected by a significant interaction of Genotype x Dose 
(Genotype*Dose: F(2, 26)=3.96, p<0.05; Dose: F(2, 26)=5.51, p=0.01); post hoc 
analysis revealed a significant effect of the highest dose (7.5 μg) in Scr:sP 
compared to vehicle condition (40% reduction). At the highest dose microinfused, 
indeed, PACAP (6-38) fully blocked the excessive ethanol intake of Scr:sP rats 
as compared to vehicle-treated Wistar rats (p=0.70). As shown in Fig. 1B and 1D, 
responding for water was unaffected by PACAP (6-38) in any of the two 
genotypes (Genotype*Dose: F(2, 26)=1.56, n.s.; Dose: F(2, 26)=0.54, n.s.). 
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Fig. 1 Effect of i.c.v. administration of PACAP(6-38) (n=7-8/group) on (A-C) 
ethanol intake and (B, D) water intake in a fixed ratio-1 schedule of reinforcement 
in Scr:sP rats (A, B) and Wistar rats (C, D). PACAP(6-38) selectively decreased 
ethanol intake without affecting water intake, selectively in Scr:sP rats. Data 
represent Mean±SEM. **p≤0.01 vs. Scr:sP vehicle-treated group; *p≤0.05 vs. 
Wistar vehicle-treated group. 
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I.c.v. PACAP (6-38) decreased the motivation to drink ethanol in alcohol-
preferring, but not in outbred rats 
 As shown in Fig. 2, Scr:sP rats showed higher breakpoint for ethanol 
compared to outbred Wistar rats under a progressive ratio schedule of 
reinforcement (Genotype: F(1, 21)=17.4, p<0.001). I.c.v. administration of the 
PAC1R antagonist PACAP (6-38) decreased the breakpoint for ethanol in Scr:sP 
rats (Fig. 2A), but not in outbred Wistar rats (Fig. 2C) (Genotype*Dose: F(2, 
42)=3.91, p<0.05; Dose: F(2, 42)=1.97, n.s.). Post hoc analysis showed that the 
highest dose of PACAP (6-38) significantly reduced the breakpoint in Scr:sP rats 
(25% of reduction vs. vehicle condition). PACAP (6-38) also reduced the total 
responses for ethanol selectively in Scr:sP rats (data not shown; Genotype: F(1, 
21) = 14.9, p<0.001; Genotype*Dose: F(2, 42)=4.49, p<0.05; Dose: F(2, 
42)=2.34, n.s.). The antagonist treatment had no effect on the number of inactive 
lever presses (Fig. 2B and 2D) (Genotype*Dose: F(2, 42)=0.42, n.s.; Dose: F(2, 
40)=1.30, n.s.). 
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Fig. 2 Effect of i.c.v. administration of PACAP(6-38) (n=11-14/group) on (A-C) 
breakpoint and (B-D) inactive lever presses in a Progressive Ratio schedule of 
reinforcement in Scr:sP rats (A, B) and Wistar rats (B, D). Data represents 
Mean±SEM. *p≤0.05, **p≤0.01 vs. Scr:sP vehicle-treated group; *p≤0.05, 
**p≤0.01, ***p≤0.001 vs. Wistar vehicle-treated group. 
 
 22 
 
I.c.v. PACAP (6-38) decreased alcohol-seeking behavior in alcohol-
preferring rats 
 As shown in Fig. 3A, PACAP (6-38) decreased alcohol-seeking behavior 
in Scr:sP rats (F(2, 18)=3.67, p<0.05; Fig. 3A) under a second-order schedule of 
reinforcement, in which an alcohol-associated conditioned stimulus maintains 
alcohol-seeking behavior. The highest dose of PACAP (6-38) significantly 
decreased the number of lever presses during the first interval (43% of 
reduction). The treatment had no effect on inactive lever presses (F(2, 18)=0.54, 
n.s.; Fig. 3B). 
 
I.c.v. PACAP (6-38) had no effect on saccharin intake in alcohol-preferring 
rats 
 As shown in Fig. 3C, i.c.v. administration of the PAC1R antagonist PACAP 
(6-38) did not affect lever pressing for a sweet, saccharin solution in Scr:sP rats 
in an FR1 schedule of reinforcement (F(2, 10)=0.13, n.s.). As desired, this 
saccharin concentration (0.02% w/v) maintained levels of responding under 
vehicle conditions that matched those obtained with ethanol (average of 37.3±4.3 
and 39.3±7.9 lever presses for ethanol and saccharin, respectively). Once again, 
PACAP(6-38) had no effect on concurrent water intake (F(2, 10)=0.71, n.s.)(Fig. 
3D).  
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Fig. 3  Effect of i.c.v. administration of PACAP(6-38) (n=10) on (A) the number of 
active lever presses and (B) inactive lever presses during the first 15-min interval 
in a second-order schedule of reinforcement in Scr:sP rats. Effect of i.c.v. 
administration of PACAP(6-38) (n=6) on (C) saccharin intake and (D) water 
intake in Scr:sP rats. PACAP(6-38) significantly decreased breakpoint selectively 
in Scr:sP rats, significantly decreased active, but not inactive, lever press 
responses in the second-order schedule and did not affect saccharin intake. Data 
represent Mean±SEM. *p≤0.05, **p≤0.01 vs. Scr:sP vehicle-treated group; 
*p≤0.05, **p≤0.01, *** p≤0.001, vs. Wistar vehicle-treated group. 
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PAC1 receptor is decreased in NAcc core of alcohol-preferring rats 
 As shown in Fig. 4 a significant decrease in PAC1R immunoreactivity 
(PAC1 positive cells) was observed in the NAcc core of Scr:sP rats, compared to 
Wistar rats (t(14)=3.71, p<0.002). No significant differences were observed in the 
NAcc shell (t(14)=1.75, n.s) or the Dorsal Striatum (t(14)=0.87, n.s.), suggesting 
regional specificity. 
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Fig. 4. Bar graph shows the number of PAC1 receptor + cells in Scr:sP and 
Wistar rats in NAcc core (right panel), NAcc shell (center panel) and DS (left 
panel) (A). Representative micrographs of PAC1 receptor immunoreactivity in 
NAcc core, NAcc shell, and DS (B). A significant decrease in PAC1 receptor + 
cells was found in Scr:sP in NAcc core. . Data represent Mean±SEM. **p≤0.01 
vs. Wistar group. 
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Dopaminergic neurons of the VTA projecting to the NAcc core co-express 
PACAP 
 Using immunofluorescence analysis of the Ventral Tegmental Area (VTA) 
we labeled (green, Fig. 5A) tyrosine hydroxylase (TH)-positive neurons, PACAP-
positive neurons (red, Fig. 5B), as well as neurons containing Fluorogold (blue, 
Fig. 5C), a retrograde axonal tracer which had been microinfused into the NAcc 
core 7 days before brain collection. We observed that all TH-positive, i.e. 
dopaminergic, neurons co-localized with PACAP, and all neurons projecting to 
the NAcc core express both TH and PACAP, as shown by triple-labeling (Fig. 5E-
5G; S1E-S1G). 
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Fig. 5. Immunofluorescence (10x) of (A) TH-positive neurons, (B) PACAP-
positive neurons, and (C) FluoroGold-labeled neurons in the VTA of rats injected 
in the NAcc core with the retrograde axonal tracer, FluoroGold. (D) TH-positive 
and FluoroGold-positive neurons, (E) TH-positive and PACAP-positive neurons, 
(F) PACAP-positive and FluoroGold-positive neurons, (G) triple-labeled neurons. 
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Fig. 6. Effect of PACAP(6-38) microinfusion in the NAcc core (n=7) on (A) 
ethanol intake and (B) water intake, and in the NAcc shell on (C) ethanol intake 
and (D) water intake in Fixed Ratio-1 in Scr:sP rats (n=7/group). PACAP(6-38) 
significantly reduced ethanol (but not water) intake when microinfused into the 
NAcc core, but not into the shell. Data represent Mean±SEM. **p≤0.01 vs. 
vehicle-treated group. (E) Illustrations of coronal rat brain slices; dots represent 
the injection sites in the NAcc core (left column) and shell (right column) included 
in the data analysis. 
 29 
 
PACAP(6-38) microinfusion in the NAcc core prevented excessive alcohol 
drinking in alcohol-preferring rats 
 Microinfusions of the PAC1R antagonist PACAP(6-38) into the NAcc core 
significantly decreased excessive ethanol intake under an FR1 schedule of 
reinforcement in Scr:sP rats (Fig. 6A, F(2, 12)=25.53, p<0.001). Post hoc 
analysis revealed that PACAP(6-38) significantly reduced ethanol intake (41% 
reduction at the highest dose). In contrast, no effects were observed when 
PACAP(6-38) was microinfused into the NAcc shell, as shown in Fig. 6C (F(2, 
12)=1.37, n.s.), supporting the immunohistochemistry findings that the NAcc core 
PAC1Rs are those involved in the control of excessive alcohol drinking. Water 
intake was not affected by PACAP(6-38) microinfusion in either subregions of the 
NAcc (core: X2(2, N=7)=0.50, n.s.; shell: X2(2, N=7)=1.68, n.s., Fig. 6B and 6D). 
Fig. 6, panel E shows the location of the inection sites in the NAcc core (left 
column) and the NAcc shell (right column) included in the data analysis.  
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DISCUSSION 
 
 This series of studies demonstrates that i.c.v. administration of the PAC1R 
antagonist PACAP(6-38) dose-dependently and selectively decreased oral 
ethanol self-administration in alcohol-preferring Scr:sP rats that drink excessive 
amounts of alcohol. The PAC1 antagonist also reduced their motivation to work 
to obtain ethanol, as seen by the decreased breaking point in the progressive 
ratio test, as well as alcohol-seeking behavior. In contrast, PACAP(6-38) did not 
reduce ethanol self-administration in control outbred Wistar rats, nor did it affect 
responding for water or for a saccharin solution, suggesting a specificity in the 
treatment for the alcohol-preferring Sardinian rats, the model of alcoholism used 
in these studies, and for alcohol intake. Ethanol naïve Scr:sP rats also showed 
decreased PAC1R expression in the NAcc core, compared to ethanol-naïve 
control Wistar rats, which suggests that there are significant underlying 
neurobiological factors that affect alcohol preference and consumption, as well 
as vulnerability to alcohol addiction. Finally, blockade of PAC1R in the NAcc 
core, but not the NAcc shell, was sufficient to prevent excessive ethanol intake in 
Scr:sP rats, also suggesting a specificity of location in the brain for the treatment. 
The results collectively support an endogenous role for the NAcc core 
PACAP/PAC1R system in controlling excessive ethanol intake and alcohol-
seeking.  
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 Central infusion of PACAP(6-38) not only blocked excessive drinking in 
alcohol-preferring rats, bringing levels back to those of control outbred rats, but it 
also reduced the breakpoint under a PR schedule of reinforcement, a measure of 
the motivation to obtain a reinforce in which the influence of local response rates  
on performance are negligible. 
  Importantly, PAC1R blockade reduced alcohol-seeking behavior, 
suggesting an effect on incentive motivational mechanisms controlling ethanol-
seeking and intake. To assess this, we used a second-order schedule of 
reinforcement; this task, used with psychostimulants and opiates (29, 30), is 
characterized by the maintenance of responding not only by the self-
administered drug, but also by the contingent presentation of drug-paired stimuli 
that serve as conditioned reinforcers of instrumental behavior (31). For example, 
the operant conditioning would include a tone or light that accompanies the 
presentation of alcohol via lever press. PACAP(6-38) dose-dependently reduced 
the number of active lever presses during the first “drug-free” interval of the 
session, suggesting an effect of PACAP(6-38) on either the incentive 
motivational mechanisms governing alcohol-seeking and intake or on the impact 
of alcohol-associated conditioned reinforcer (environmental cues) to maintain 
responding (30, 31). Importantly, this would provide effective treatment in 
addiction as many addictions, including alcohol, include cue-induced or 
environmentally induced binge drinking. 
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 It is interesting to note that the antagonist did not alter self-administration 
of an equally reinforcing sweet solution (i.e. producing the same number of lever 
presses as the subject produced for 10% alcohol solution under vehicle 
conditions), suggesting not only that PACAP(6-38) does not produce malaise-like 
or other unspecific behaviors, but also that the effects of PACAP(6-38) are 
selective for alcohol. The specificity of drug treatment effects suggests that the 
PACAP receptor system plays a functional role when the brain reward system is 
activated specifically by alcohol but plays only a limited role in the regulation of 
processes activated by sweet taste; the effect of the treatment must therefore not 
have an effect through taste or smell or caloric value. A simple reduction in 
caloric intake by PACAP(6-38) can be excluded based on the extensive literature 
showing that PACAP itself (and not PACAP receptor antagonists) potently 
reduces food intake. 
 The observed selective effect of the PAC1R antagonist in alcohol-
preferring Scr:sP rats led us to hypothesize that neuroadaptations in PAC1R 
could be responsible for the excessive drinking phenotype. Using 
immunohistochemistry we found that PAC1R protein levels were significantly 
lower (-38%) in the NAcc core of Scr:sP rats, compared to outbred Wistar rats. 
Similar changes were not observed in NAcc shell or Dorsal Striatum, suggesting 
regional specificity. The present experiments have, therefore, identified a pre-
existing difference in the PACAP/PAC1R system in the NAcc core of Scr:sP rats 
as compared to their own outbred stock, which is associated with their genetic 
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propensity to consume alcohol as well as propagate alcohol-seeking behavior. 
Other cases of increased sensitivity to antagonists associated with decreased 
density or coupling of the respective receptor have been reported (34, 35). If 
PACAP is considered a mediator of brain reward function, a parallel can be 
drawn between a hypo-PACAPergic state and the hypo-dopaminergic state 
widely reported for alcoholic patients as well as alcohol-preferring rats and linked 
to the vulnerability to consume excessive amounts of alcohol (36, 37). It can be 
debated, then, that the low levels of PACAP would be due to a shift into the 
negative reinforcement phase and therefore a transition into addiction. With less 
PACAP or PAC1Rs, the baseline for activation of the reward circuit would be 
higher due to a lower effect of the PACAP stress response, thus not feeling the 
negative reinforcement due to PACAP. Low levels of PAC1Rs in Scr:sP rats may 
predispose subjects to drink excessively as a means of compensating for the 
decrease in activation of downstream reward circuits and therefore, for a deficit in 
PACAP-regulated reward circuit functions since more alcohol would be needed 
to activate the reward circuit to the degree of a wild-type subject.  Finally, albeit 
basally reduced, the system may be hyper-responsive to alcohol, like other 
systems (38). In this study we measured PAC1R levels in alcohol-naïve rats, 
rather than in rats self-administering ethanol, because ethanol can be a 
confounding factor while attempting to identify differences between genotypes 
(32, 33); it would be valuable in future studies to also examine brain changes 
resulting from alcohol drinking. An alternative hypothesis may involve the re-
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sensitization of the PAC1 receptor by the antagonist and therefore an 
improvement of the PAC1-mediated reward function upon administration of the 
PAC1 antagonist. This hypothesis is supported by in vitro evidence that chronic 
administration of PACAP desensitizes PACAP-induced cAMP accumulation, 
while PACAP(6-38) re-sensitizes it in the chicken retina (39). 
 In support of the functional significance of the observed dysregulation of 
PAC1R in the NAcc core of Scr:sP rats and in agreement with our predictions, 
excessive ethanol responding in Scr:sP rats was suppressed following PACAP(6-
38) microinfusion into the NAcc core, but not into the shell. The reduction of 
ethanol responding following intra-NAcc core administration was observed at 
doses which were significantly lower (0.5 and 1.25 μg/side) than those which 
reduced ethanol self-administration following i.c.v. administration (7.5 μg/rat), 
suggesting that the Scr:sP rats were inherently more sensitive to the treatment 
due to a decreased level of PAC1Rs in the NAcc core as compared to the 
reduced ethanol self-administration group. 
 The NAcc core has been suggested to be a mediator of Pavlovian 
influences on instrumental action (40, 41). A role for the NAcc core in the 
acquisition of drug seeking maintained by drug-associated cues has been 
suggested; furthermore, evidence supports the development of neuroadaptations 
in the NAcc core following alcohol (and drug) consumption over extended periods 
of time, suggesting neuroplasticity (42-44).  Human imaging studies with 
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detoxified alcoholics have also shown activation of the NAcc core during 
exposure to alcohol-associated cues (45). 
 Importantly, the immunofluorescence data demonstrate in vivo that 
dopaminergic neurons of the VTA also express PACAP, and that VTA neurons 
projecting to the NAcc core are indeed DA/PACAP neurons, suggesting a 
relationship between dopamine and PACAP pathways. In vitro work indicated 
that PACAP increases transcription of the genes of both tyrosine hydroxylase 
(TH), a key enzyme in the production of dopamine, and vesicular monoamine 
transporter (VMAT), a transport protein necessary for transporting dopamine into 
vesicles for synaptic transmission, via PAC1 (46, 47). Furthermore, PACAP acts 
as a secretagogue to elicit catecholamine secretion in chromaffin cells and PC12 
cells (48 49). And it is involved in dexamethasone-induced dopamine 
biosynthesis (50). Only a portion of the TH-positive VTA neurons expressed the 
retrograde tracer FluoroGold and were therefore projections to the NAcc core; 
this was expected as dopaminergic neurons of the VTA are known to project 
other areas, including the NAcc shell, prefrontal cortex, and central amygdala 
(51). In the VTA, co-localizations of TH with other neuropeptides have been 
demonstrated (e.g. neurotensin and cholecystokinin (52)). Due to the nearly 
complete overlap between dopaminergic and PACAPergic neurons of the VTA 
projecting to the NAcc core, PACAP and dopamine may be co-released in this 
area depending on firing frequencies, as shown in other neuropeptides co-
localized with classical neurotransmitters (53, 54).  
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 Based on our data, the likelihood that PACAP is released from VTA 
mesolimbic neurons in the NAcc following alcohol consumption is high, thereby 
contributing to the maintenance of high levels of intake via PAC1R activation. 
Our data lead us to speculate that reduction of excessive ethanol intake after 
intra-NAcc injection of PACAP(6-38) results from the ability of the antagonist to 
prevent alcohol-induced potentiation of mesolimbic dopaminergic 
neurotransmission by PACAP, selectively in alcohol-preferring rats, which would 
reduce the activity of the PAC1R receptors that activate the reward circuit within 
the VTA. This hypothesis is in agreement with the observation of higher 
spontaneous firing rates of dopaminergic VTA neurons in alcohol-preferring rats 
(55).  Therefore, the observed innate dysregulation of the PACAP/PAC1R 
system in alcohol-preferring Scr:sP rats may be linked to the increased sensitivity 
of the dopaminergic system to ethanol and, in turn, to the vulnerability to alcohol 
addiction. With an increased effect of dopamine, the addictive properties of 
alcohol, i.e. the overstimulation of the brain reward system, would increase 
alcohol consumption while possibly reducing the stress response system that has 
been shown to be linked to PACAP and CRF, which would also increase alcohol 
consumption due to lesser negative consequence. 
 In conclusion, our behavioral and molecular findings provide evidence that 
a dysregulation of the PACAP/PAC1R system in the NAcc core is predictive of a 
vulnerability to drink excessive amounts of alcohol. Importantly, blockade of the 
PAC1R reveals selectivity in this treatment, as saccharin and water intake were 
 37 
 
not affected by the drug. Because of the link between dopaminergic and 
PACAPergic neurons in the VTA, as shown through our immunohistochemical 
findings, it is plausible that the PACAP/PAC1R system plays a key role in the 
development and progression of addiction via its possible role in the brain’s 
reward system. Blockade of PAC1Rs dramatically reduces consumption, 
motivation, and seeking of alcohol, as shown by the procedures we have 
demonstrated in our studies, identifying the PACAP/PAC1R system as a 
promising therapeutic target for the treatment of alcohol addiction.  
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